ZacharskiL.R., WojtukiewiczM.Z., CostantiniV., OrnsteinD.L., MemoliV.A.Pathways of coagulation/fibronolysis activation in malignacy.Sem Thrombosis Hemostasis1992; 18: 104–16.
2.
DuffyM.J., ReillyD., O'sullivanC., O'HigginoN., FennellyJ.J., AndreasenP.Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.Cancer Res1990; 50: 6827–9.
3.
FoucreD., BouchetC., HaceneK.Relationship between cathepsin D, urokinase and plasminogen activator inhibitors in malignant vs benign breast tumors.Br J Cancer1991; 64: 926–32.
4.
FoekensJ.A., SchmittM., Van PuttenW.L.J.Prognostic value of urokinase - type plasminogen activator in 671 primary breast cancer patients.Cancer Res1992; 52: 6101–5.
5.
JänickeF., SchmittM., PacheL.Urokinase plasminogen activator (u-PA) and its inhibitor PAI-I are strong and independent prognostic factors in node negative breast tumors.Breast Cancer Res Treat1993; 24: 195–208.
6.
SumiyoshiK., BabaS., SokaguchiS., UranoT., TakadaY., TakadaA.Increase in levels of plasminogen activator and type I plasminogen activator inhibitor in human breast cancer. Possible roles in human progression and metastasis.Thromb Res1991; 63: 59–71.
7.
SumisyoshiK., SerizawaK., UranoT., TakadaY., TakadaA., BabaS.Plasminogen activator system in human breast cancer.Int J Cancer1992; 50: 345–8.
8.
DuffyM.J., O'GradyP., DevaneyD., O'siorainL., FenellyJ.O., LijnenH.R.Tissue-type plasminogen activator, a new prognostic marker in breast cancer.Cancer Res1988; 48: 1348–9.
9.
SchmittM., JänickeF., GraeffH.Tumor-associated fibronolysis: the prognostic relevance of plasminogen activator uPA and tPA in human breast cancer.Blood Coagulation Fibronolysis1990; 1: 695–702.
10.
NeedhamG.K., NicholsonS., AngurB., FarndonJ.R., HarrisA.L.Relationship of membrane bound tissue type and urokinase type plasminogen activators in human breast cancer to estrogen and epidermal growth factor receptors.Cancer Res1988; 48: 6603–7.
11.
FernándezFernández Ma, Fernández LlanaB., Fernández RaigosoP., RoizMaC, AllendeMaT, RuibalA.CAM26 cytosol levels seem to be correlated with pS2 expression in breast cancer.Int J Biol Markers1993, 8: 25–6.
12.
FoekensJ.A., Van PuttenW.L.J., PortengenH.Prognostic value of pS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.J Clin Oncol1993; 11: 899–908.
13.
CorrealeM., ParadisoA., AbbateI.Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with tumor proliferative activity.Tumor Biol1993; 14: 30–7.
14.
FoekensJ.A., RioM.C., SeguinP.Prediction of relapse and survival in breast cancer patients by pS2 protein status.Cancer Res1990; 50: 3832–7.
15.
RellaC., CovielloM., QuarantaM., ParadisoA.Tissue-type plasminogen activator as marker of functional steroid receptors in human breast cancer.Thromb Res1993; 69: 209–20.
